Cancer Communications
indexed by SCI
BMC

Research highlight
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
Trace M. Jones, Claudia Espitia, Wei Wang, Steffan T. Nawrocki & Jennifer S. Carew
University of Arizona Cancer Center, Tucson, AZ, 85724, USA Division of Translational and Regenerative Medicine, Department of Medicine, University of Arizona, Tucson, AZ, 85721, USA
[Abstract] N/A
Cancer Communications   Epub date: 11/9/2019   doi:10.1186/s40880-019-0418-0
[PDF Full-text]

[ Html full-text] (BioMed Central)

[ PubMed]

Cite this article

Trace M. Jones, Claudia Espitia, Wei Wang, Steffan T. Nawrocki & Jennifer S. Carew. Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies. Cancer Commun (Lond). 2019, 39:72. doi:10.1186/s40880-019-0418-0


Export citations

EndNote

CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by BioMed Central

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China